Real-World PRRT in 104 NET Patients: Small Bowel Tumors Respond Best, But Serious Toxicities Include Liver Failure and Nephrotic Syndrome
In 104 neuroendocrine tumor patients treated with 177Lu-DOTATATE PRRT, 74% completed all four cycles with an 18% response rate, but small bowel NETs had significantly longer time-to-failure than pancreatic NETs (37.3 vs 13.2 months), and serious adverse events occurred in ~40% of patients.
Quick Facts
What This Study Found
74% completed all 4 PRRT cycles; 18% objective response rate. Small bowel NETs: median TTF 37.3 months vs pancreatic NETs 13.2 months (p=0.001). Independent predictors of TTF: Ki-67, primary site, liver tumor burden ≥50%. ~40% had grade ≥3 AEs. 10% discontinued for treatment-related AEs. 2 delayed nephrotic syndrome cases. 6 patients had rapid liver failure progression.
Key Numbers
104 patients. 177Lu-DOTATATE 200 mCi administered every 8 weeks for 4 doses. December 2017 to October 2020.
How They Did This
Retrospective single-center analysis of 104 NET patients treated with 177Lu-DOTATATE (200 mCi every 8 weeks for 4 doses) at a US academic center from December 2017 to October 2020. Outcomes: objective response rate, time-to-treatment failure/death, adverse events. Multivariate analysis for predictive factors.
Why This Research Matters
PRRT is increasingly used for advanced NETs, but clinical trial data (NETTER-1) included mostly small bowel NETs. This real-world study provides critical safety and efficacy data across NET subtypes, identifies patients at highest risk for serious complications, and reports previously unrecognized toxicities like delayed nephrotic syndrome.
The Bigger Picture
As PRRT becomes more widely used for NETs, understanding real-world outcomes and toxicities is essential. This study reveals that not all NETs respond equally — pancreatic NETs fare significantly worse — and identifies serious adverse events (liver failure, delayed kidney damage) not well-characterized in pivotal trials.
What This Study Doesn't Tell Us
Retrospective single-center study with inherent selection bias. No control group. Heterogeneous NET types and prior treatments. Small numbers for subgroup analyses of rare toxicities (2 nephrotic syndrome, 6 liver failure). Median follow-up not clearly stated.
Questions This Raises
- ?Should PRRT treatment protocols be modified for pancreatic NETs given their significantly worse outcomes?
- ?What risk factors predict the rare but devastating rapid liver failure progression after PRRT?
- ?Should routine kidney monitoring be extended to 2+ years post-PRRT given the delayed nephrotic syndrome cases?
Trust & Context
- Key Stat:
- 37.3 vs 13.2 months Small bowel NETs had nearly 3x longer time-to-treatment failure than pancreatic NETs after PRRT, highlighting dramatic differences in response by tumor type
- Evidence Grade:
- Rated moderate: reasonably sized cohort (104 patients) with real-world data, but limited by retrospective single-center design without a control group.
- Study Age:
- Published in 2024. Covers patients treated from December 2017 to October 2020, providing mature follow-up data.
- Original Title:
- Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
- Published In:
- PloS one, 19(5), e0298824 (2024)
- Authors:
- Sukrithan, Vineeth, Armbruster, Heather, Rogers, Sherise, Vogt, Sherry Mori, Grenade, Cassandra, Verschraegen, Claire, Zhou, Ye, Goyal, Ashima, Natwa, Mona, Hussein, Akram, Barr, Hallie, Konate, Dramane, Batdorf, Rochelle, Brown, Andrew, Williams, Bonnie, Zhao, Songzhu, Wei, Lai, Xu, Menglin, Shah, Manisha H, Konda, Bhavana
- Database ID:
- RPEP-09341
Evidence Hierarchy
Frequently Asked Questions
What is PRRT and how well does it work for neuroendocrine tumors?
PRRT (peptide receptor radionuclide therapy) delivers targeted radiation to tumors using a radiolabeled peptide that binds somatostatin receptors on NET cells. In this real-world study, 18% of patients had measurable tumor shrinkage and small bowel tumors responded for an average of 37 months. However, pancreatic tumors responded for only 13 months.
Is PRRT safe? What are the side effects?
Most patients (74%) completed all four treatment cycles, but about 40% experienced serious side effects. Common issues include blood count changes and nausea. This study also identified rare but serious risks: 2 patients developed kidney disease 14-27 months later, and 6 patients had rapid liver failure. Patients with existing mesenteric disease had higher bowel complication risks.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09341APA
Sukrithan, Vineeth; Armbruster, Heather; Rogers, Sherise; Vogt, Sherry Mori; Grenade, Cassandra; Verschraegen, Claire; Zhou, Ye; Goyal, Ashima; Natwa, Mona; Hussein, Akram; Barr, Hallie; Konate, Dramane; Batdorf, Rochelle; Brown, Andrew; Williams, Bonnie; Zhao, Songzhu; Wei, Lai; Xu, Menglin; Shah, Manisha H; Konda, Bhavana. (2024). Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.. PloS one, 19(5), e0298824. https://doi.org/10.1371/journal.pone.0298824
MLA
Sukrithan, Vineeth, et al. "Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.." PloS one, 2024. https://doi.org/10.1371/journal.pone.0298824
RethinkPeptides
RethinkPeptides Research Database. "Safety and efficacy of peptide receptor radionuclide therapy..." RPEP-09341. Retrieved from https://rethinkpeptides.com/research/sukrithan-2024-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.